Fusion Pharmaceuticals
phase trial a first of its kind antibody based targeted alpha therapy study for solid tumors well established cancer found on parent told antibody to or binding | Fusion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
17 of 26
Related slides by other companies
MAIA Biotechnology
Investor Presentation
July 2023
thio trial planned thio | MAIA Biotechnology
Mink Therapeutics
IPO
October 2021
phase clinical trial focused in solid tumors | Mink Therapeutics
TCR2 Therapeutics
Results
September 2022
phase trial in solid tumors | TCR2 Therapeutics
MAIA Biotechnology
Investor Presentation
October 2023
thio trial planned to expand best combination arms | MAIA Biotechnology
Other recent decks by Fusion Pharmaceuticals
See all presentations (4 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
IPO
June 2020
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io